Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MPLT
MPLT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MPLT News
FCPM III Reduces Stake in Dyne Therapeutics by $14 Million
1d ago
Yahoo Finance
Wall Street's Latest Rating Changes Overview
4d ago
CNBC
MapLight CFO's Stock Sale Raises Investor Concerns
May 15 2026
Fool
MapLight Therapeutics Reports Q1 Losses and Cash Position
May 15 2026
seekingalpha
MapLight Therapeutics Executive Sells Shares
May 04 2026
Fool
MapLight Completes Enrollment in Schizophrenia Trial
May 01 2026
NASDAQ.COM
Analysis of MapLight Therapeutics' Cash Burn
Apr 26 2026
Yahoo Finance
MapLight Therapeutics Executive Sells Shares Amid Routine Liquidity Management
Apr 22 2026
Fool
Biotech Stocks Reach New 52-Week Highs
Apr 09 2026
NASDAQ.COM
MapLight Reports 2025 Financial Results and Clinical Milestones
Mar 26 2026
NASDAQ.COM
MapLight Therapeutics Reports Q4 Financial Results
Mar 26 2026
seekingalpha
Maplight Therapeutics Inc. Reports Q4 Net Loss of $79.5 Million, Q4 EPS at -$2.47
Mar 26 2026
moomoo
Maplight and CVRx Executives Increase Stock Holdings
Feb 23 2026
NASDAQ.COM
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
Jan 09 2026
renaissancecapital
MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies
Jan 09 2026
Globenewswire
MapLight Therapeutics Receives FDA Fast Track Designation for ML-007C-MA in Alzheimer's Treatment
Jan 05 2026
NASDAQ.COM
Show More News
